On the 13th of December, Moderna, and Merck announced a new investigational mRNA cancer vaccine. According to the study conducted, the vaccine proved efficient, giving hope to skin cancer patients. The company pioneering mRNA technology developed an investigational personalized vaccine, which, in combination with Merck & Co.’s immunotherapy Keytruda, proved efficient in the adjuvant treatment …
